Close Menu

Douglas Scientific

LGC provides customers across multiple markets with reference materials, proficiency testing, oligonucleotides, genomics reagents, and instrumentation.

The UK-based firm plans to marry its core strengths with the probes and PCR platforms, and to build its sales force in the US. 

LGC said it plans to use Douglas Scientific's PCR and qPCR platforms to provide customers with enhanced high-throughput genotyping and qPCR instruments.

The automated platform runs a higher-throughput version of the firm's Array Tape.

NEW YORK (GenomeWeb) – LGC will distribute Douglas Scientific's Array Tape laboratory automation platform in Europe, the Middle East, and Africa, according to an agreement announced today.

EnviroLogix and Douglas Scientific said today that they have signed a multi-year exclusive distribution agreement pairing EnviroLogix's patent-pending DNAble technology with Douglas Scientific's Array Tape platform.

EnviroLogix said this week that it has entered into a collaboration with Douglas Scientific to develop and optimize products for high-throughput real-time and endpoint nucleic acid analysis.

NEW YORK (GenomeWeb News) – EnviroLogix today announced an agreement with Douglas Scientific to develop and optimize solutions for high-throughput real-time and endpoint nucleic acid analysis.

Life Technologies and Douglas Scientific late last week announced a collaboration and co-marketing agreement to pair Life Tech's TaqMan real-time PCR assays with Douglas Scientific's Array Tape platform for high-throughput genotyping applications.

NEW YORK (GenomeWeb News) – Life Technologies and Douglas Scientific today announced a collaboration aimed at high-throughput genotyping.

Pages

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.